Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors
The differences in the initial TME of patients, especially in tumor-infiltrating T lymphocytes, may be potential biomarkers for predicting response and prognosis. This finding provides clues to search for biomarkers for this triple combination therapy in advanced HCC.
Authors
- Zhiqiang Wu (ORCID: https://orcid.org/0000-0002-1800-9527)
- Lihua Zhao (ORCID: https://orcid.org/0000-0002-7175-5174)
- Hongjie Cai (ORCID: https://orcid.org/0000-0001-9666-3172)
- Huaibo Sun (ORCID: https://orcid.org/0009-0000-8943-7679)
- Wenbo Guo (ORCID: https://orcid.org/0000-0002-1017-4640)
- Fan Wang
- Lijia Wu
- Song Chen
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Genecast (China) (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-11-23
- DOI
- https://doi.org/10.1016/j.intimp.2024.113662
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37